FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
Petr Novák(Institute of Chemistry of the Slovak Academy of Sciences), Michal Novák(AXON Neuroscience (Cyprus))
Cited by 141
Related Papers
No related papers found
Powered by citation graph analysis